![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Comanche will initiate a clinical study of CBP-4888, a fixed-dose combination of two small interfering ribonucleic acid (siRNAs) duplex oligonucleotides targeting soluble fms-like tyrosine kinase–1 (sFLT1) mRNA isoformse, in pregnant preeclamptic patients.
Lead Product(s): CBP-4888
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: CBP-4888
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Google Ventures
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 17, 2024
Details:
CBP-4888 is a fixed-dose combination of siRNA-2283 and siRNA-2519 targeting two soluble fms-like tyrosine kinase–1 (sFLT1) mRNA isoforms, which is investigated for the treatment of sFlt-1 mediated pre-term preeclampsia.
Lead Product(s): siRNA-2283,siRNA-2519
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: CBP-4888
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
CBP-4888 is a fixed-dose combination of two chemically-synthesized, lipid-conjugated siRNAs duplex oligonucleotides (siRNA-2283 and siRNA-2519) targeting and decreasing the production of soluble fms-like tyrosine kinase-1 in the placenta, as a treament for preeclampsia.
Lead Product(s): CBP-4888
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: CBP-4888
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023